Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5853395 | 0.85 | GABRA1 (0.46) | TAAR1GABRA1GABRB2KDM4EHTR1A | |
| SCHEMBL3672443 | 0.85 | TAAR1 (0.48) | TAAR1MAOBIDO1AOC3HTT | |
| SCHEMBL2554785 | 0.84 | GABRA1 (0.50) | TAAR1GABRA1GABRB2HTR1APNMT | |
| SCHEMBL21136476 | 0.84 | TAAR1 (0.45) | TAAR1MAOBKDM4EIDO1AOC3 | |
| SCHEMBL27689459 | 0.83 | TAAR1 (0.43) | TAAR1MAOBIDO1ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL10351311 | 0.82 | GABRA1 (0.48) | TAAR1GABRA1GABRB2HTR1APNMT | |
| SCHEMBL12082037 | 0.80 | GABRA1 (0.46) | TAAR1GABRA1GABRB2HTR1APNMT | |
| SCHEMBL13084 | 0.79 | TAAR1 (0.54) | TAAR1MAOBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL320965 | 0.79 | GABRA1 (0.46) | TAAR1GABRA1GABRB2KDM4EHTR1A | |
| SCHEMBL14140079 | 0.79 | GABRA1 (0.41) | TAAR1GABRA1GABRB2KDM4EHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162868-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162868-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | TAAR1 1715/4885GABRA1 137/4885GABRB2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.